Category Press Releases

Novartis Strikes Deal to Purchase Mariana Oncology, Bolstering Radioligand Therapy Portfolio

Novartis to Acquire Mariana Oncology, Enhancing Radioligand Therapy Portfolio Novartis has announced its agreement to acquire Mariana Oncology, a biotechnology company headquartered in Watertown, Massachusetts, specializing in the development of innovative radioligand therapies (RLTs) for cancers with significant unmet medical…

Read MoreNovartis Strikes Deal to Purchase Mariana Oncology, Bolstering Radioligand Therapy Portfolio

WuXi AppTec Surpasses First Quarter 2024 Goals Amid External Obstacles, Sustaining Operational Stability

WuXi AppTec, a leading global provider of R&D and manufacturing services for the pharmaceutical and life sciences industry, has released its financial results for the first quarter ending March 31, 2024. Here’s a breakdown of the key highlights from the…

Read MoreWuXi AppTec Surpasses First Quarter 2024 Goals Amid External Obstacles, Sustaining Operational Stability

European Commission Grants Approval for KALYDECO® to Treat Cystic Fibrosis in Infants as Young as 1 Month Old, Announces Vertex

Vertex Pharmaceuticals (Nasdaq: VRTX) has received approval from the European Commission for the expansion of KALYDECO® (ivacaftor) labeling. This approval allows for the treatment of infants as young as 1 month old with cystic fibrosis (CF) who possess specific mutations…

Read MoreEuropean Commission Grants Approval for KALYDECO® to Treat Cystic Fibrosis in Infants as Young as 1 Month Old, Announces Vertex

FDA Grants Approval to Pfizer’s BEQVEZ™: A Single-Dose Gene Therapy for Hemophilia B in Adults

Today, Pfizer Inc. (NYSE: PFE) announced the approval of BEQVEZ™ (fidanacogene elaparvovec-dzkt) by the U.S. Food and Drug Administration (FDA) for the treatment of adults grappling with moderate to severe hemophilia B. This approval is particularly significant for individuals currently…

Read MoreFDA Grants Approval to Pfizer’s BEQVEZ™: A Single-Dose Gene Therapy for Hemophilia B in Adults

Moderna Secures Deal to Provide 12.5 Million COVID-19 Vaccines for Brazil’s National Vaccination Drive

Moderna, Inc. (NASDAQ: MRNA) has announced a significant milestone in its global efforts to combat COVID-19 by securing a contract with Brazil’s Ministry of Health (Ministério da Saúde). The contract entails supplying Moderna’s mRNA COVID-19 vaccine as a crucial component…

Read MoreModerna Secures Deal to Provide 12.5 Million COVID-19 Vaccines for Brazil’s National Vaccination Drive

Vertex Announces Advancements of Suzetrigine (VX-548) in Acute and Neuropathic Pain

Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) has unveiled significant progress in its suzetrigine pain program, potentially introducing the first new class of medication for acute and neuropathic pain in over twenty years. Suzetrigine, an oral selective NaV1.8 pain signal inhibitor (previously…

Read MoreVertex Announces Advancements of Suzetrigine (VX-548) in Acute and Neuropathic Pain

Six-Year Efficacy of Novartis Kesimpta® in Relapsing MS Treatment-Naïve Patients

Novartis has revealed findings from the ALITHIOS open-label extension study, demonstrating the sustained efficacy of continuous Kesimpta® (ofatumumab) treatment for up to six years in individuals recently diagnosed with relapsing multiple sclerosis (RMS). These individuals, termed “treatment-naïve,” initiated treatment within…

Read MoreSix-Year Efficacy of Novartis Kesimpta® in Relapsing MS Treatment-Naïve Patients